ZIVO — Zivo Bioscience, Inc.

OTC · Health Care · Biotechnology · CIK 1101026 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Sep 2025 65,625 21,288 -1,018,343 -1,033,056 559,452 57,222 3,846,055
Jun 2025 53,400 17,922 -1,632,872 -1,640,232 703,327 9,823 3,244,073
Mar 2025 0 0 -4,208,788 -4,211,188 1,331,334 517,189 2,948,613
Dec 2024 90,000 27,000 -1,596,419 -1,601,385 1,643,122 1,542,442 2,158,019

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,078,926
Investing CF
$0
Financing CF
$2,976,745
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.82
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-143,851,025
Inventory
Receivables
$0
ST Investments
EBIT TTM
$-8,458,176
Pretax Income TTM
$-8,485,861
Interest Exp TTM
$27,685
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$209,025
EBITDA
Free Cash Flow
$-2,617,243
Enterprise Value
$17,289,002
Total Cash
$57,222
Total Debt
$819,695
Shares Out
4,215,112
Trailing EPS
$-2.19
Book Value
$-0.86
ROE
ROA
-1001.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 157,220 -13,361,897 -13,384,836 1,643,122 2,158,019 -4,313,510
Dec 2023 27,650 -7,263,012 -7,777,184 555,715 2,761,558 -5,799,893
Dec 2022 0 -8,731,974 -8,745,293 2,123,019 2,133,641 -7,102,612
Dec 2021 0 -8,645,119 -8,755,881 8,990,178 2,947,969 -6,803,333

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.20

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $239.95B $443.84
GILD GILEAD SCIENCES, INC. $181.95B $146.74
ARGX ARGENX SE $63.26B $1011.11
MRNA Moderna, Inc. $55.45B $138.89
RVMD Revolution Medicines, Inc. $45.35B $211.58

News headlines (Yahoo Finance, 1h cache)

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
2026-06-26 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
2026-06-23 12:35 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.